Thiazolidinediones and macular edema

Archives of Internal Medicine

Volumn 172, Issue 13, 2012, Pages 1011-1013

  Singh, Sonal ^a   Segal, Jodi B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

BLADDER CANCER; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CROSS-SECTIONAL STUDY; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG MARKETING; FRACTURE; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PERIPHERAL EDEMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RETINA MACULA EDEMA; RETROSPECTIVE STUDY; SELF REPORT;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MACULAR EDEMA; MALE; THIAZOLIDINEDIONES;

EID: 84863705247     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.2461     Document Type: Note

References (11)

1. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602-613.
2. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-1195. (Pubitemid 47403105)
3. Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol. 2012;96(3):345-349.
4. Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes [published online June 11, 2012]. Arch Intern Med. 2012;172(13):1005-1011.
5. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920. (Pubitemid 37323253)
6. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol. 2009;147(4):583-586, e1.
7. Motola D, Piccinni C, Biagi C, et al. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf. 2012;35(4):315-323.
8. Ambrosius WT, Danis RP, Goff DC Jr, et al ACCORD Study Group. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol. 2010;128(3):312-318.
9. Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008; 126(6):793-799. (Pubitemid 351831328)
10. Home PD, Pocock SJ, Beck-Nielsen H, et al RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135.
11. Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289. (Pubitemid 41416583)